Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
Investors are beginning to turn cautious on biotechnology stocks as a rapid rise in Treasury yields dents the appeal for shares of companies that are often viewed as risky all-or-nothing bets on breakthrough medical treatments.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)